Literature DB >> 34062264

Curing pancreatic cancer.

Benno Traub1, Karl-Heinz Link2, Marko Kornmann3.   

Abstract

The distinct biology of pancreatic cancer with aggressive and early invasive tumor cells, a tumor promoting microenvironment, late diagnosis, and high therapy resistance poses major challenges on clinicians, researchers, and patients. In current clinical practice, a curative approach for pancreatic cancer can only be offered to a minority of patients and even for those patients, the long-term outcome is grim. This bitter combination will eventually let pancreatic cancer rise to the second leading cause of cancer-related mortalities. With surgery being the only curative option, complete tumor resection still remains the center of pancreatic cancer treatment. In recent years, new developments in neoadjuvant and adjuvant treatment have emerged. Together with improved perioperative care including complication management, an increasing number of patients have become eligible for tumor resection. Basic research aims to further increase these numbers by new methods of early detection, better tumor modelling and personalized treatment options. This review aims to summarize the current knowledge on clinical and biologic features, surgical and non-surgical treatment options, and the improved collaboration of clinicians and basic researchers in pancreatic cancer that will hopefully result in more successful ways of curing pancreatic cancer.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Keywords:  (Neo-)adjuvant treatment; Oncogenesis; Pancreatic cancer; Surgery; Translational research

Mesh:

Year:  2021        PMID: 34062264     DOI: 10.1016/j.semcancer.2021.05.030

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  5 in total

1.  Editorial: Multimodality Treatment in Pancreatic Ductal Adenocarcinoma - Current Options and the Future Impact of Molecular Biological Profiling.

Authors:  Marko Kornmann; Alexander Kleger
Journal:  Visc Med       Date:  2022-01-24

Review 2.  The Trinity: Interplay among Cancer Cells, Fibroblasts, and Immune Cells in Pancreatic Cancer and Implication of CD8+ T Cell-Orientated Therapy.

Authors:  Yu-Hsuan Hung; Li-Tzong Chen; Wen-Chun Hung
Journal:  Biomedicines       Date:  2022-04-18

3.  Loss of Interleukin-13-Receptor-Alpha-1 Induces Apoptosis and Promotes EMT in Pancreatic Cancer.

Authors:  Jingwei Shi; Xiao Shen; Qi Kang; Xing Yang; Maximilian Denzinger; Marko Kornmann; Benno Traub
Journal:  Int J Mol Sci       Date:  2022-03-26       Impact factor: 5.923

4.  4-Acetylantroquinonol B enhances cell death and inhibits autophagy by downregulating the PI3K/Akt/MDR1 pathway in gemcitabine-resistant pancreatic cancer cells.

Authors:  Ying-Yin Chen; Sheng-Yi Chen; Tsung-Ju Li; Ting-Wei Lin; Chin-Chu Chen; Gow-Chin Yen
Journal:  Oncol Lett       Date:  2022-02-18       Impact factor: 2.967

5.  LncRNA MALAT1 regulates METTL3-mediated PD-L1 expression and immune infiltrates in pancreatic cancer.

Authors:  Zhengwei Song; Xiaoguang Wang; Fei Chen; Qiuli Chen; Wenjun Liu; Xiaodan Yang; Xun Zhu; Xiaorong Liu; Peter Wang
Journal:  Front Oncol       Date:  2022-09-21       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.